Clinical Trials

234 enrolled

Phase 3 Not yet recruiting

Carcinoma, Hepatocellular

NCT06093425 2025-12-17

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

820 enrolled

Stomach Neoplasms

NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

116 enrolled

Advanced Hepatocellular Carcinoma (HCC)

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

160 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06400160 2025-11-25

Clinical Trial of TB511 in Advanced Solid Tumors

GastrointestinalGenitourinary

12 enrolled

Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Phase NA Not yet recruiting

Biliary Tract Neoplasms

NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

98 enrolled

Esophageal Squamous Cell Carcinoma

NCT04901741 2025-06-27

OPTIMUS

60 enrolled

Pancreatic Neoplasms

NCT06646445 2025-06-13

PREMICES

60 enrolled

Phase 2/3 Not yet recruiting

Turcot syndrome, Colonic Neoplasms, Microsatellite Instability

NCT06923475 2025-04-11

NEODISCO

150 enrolled

Cholangiocarcinoma, Klatskin Tumor

NCT06484153 2024-07-03

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

25 enrolled

Phase 3 Not yet recruiting

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma

NCT06411171 2024-05-17

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

36 enrolled

Gastroesophageal Junction Cancer

NCT05909423 2023-06-18

FLU-IMMUNE

21 enrolled